Stay updated with breaking news from Alimera Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Alimera Sciences, Inc. (NASDAQ:ALIM – Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.40 and traded as high as $3.71. Alimera Sciences shares last traded at $3.59, with a volume of 12,211 shares trading hands. Wall Street Analysts Forecast […]
/PRNewswire/ -- The "Ocular Drug Delivery Devices Market: Global Market Size, Forecast, Insights, and Competitive Landscape" report has been added to...
StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research note released on Tuesday. The firm issued a buy rating on the biopharmaceutical company’s stock. Several other brokerages have also commented on ALIM. Alliance Global Partners raised Alimera Sciences from a neutral rating to a buy rating in a report […]
StockNews.com started coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research note published on Tuesday. The firm issued a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also recently issued reports on ALIM. Alliance Global Partners upgraded shares of Alimera Sciences from a neutral rating […]
StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research note published on Monday. The firm issued a buy rating on the biopharmaceutical company’s stock. Other research analysts have also issued research reports about the company. Alliance Global Partners upgraded Alimera Sciences from a neutral rating to a buy rating […]